Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Stock Information for Aptevo Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aptevo Therapeutics Inc.

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
Aptevo Therapeutics Provides Pipeline Update
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
Aptevo to Present at Bio-Europe Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.